Zhang L, Xu M, Zhang W, Zhu C, Cui Z, Fu H, Ma Y, Huang S, Cui J, Liang S, Huang L, Wang H. Three-dimensional genome panorama comprehensively reveals patterns of spatial gene regulation in papillary and anaplastic thyroid cancers: a research utilizing consultant cell strains for every most cancers kind. Cell Mol Biol Lett. 2023;28(1):1.
Pugliese M, Fortunati N, Germano A, Asioli S, Marano F, Palestini N, Frairia R, Boccuzzi G, Catalano MG. Histone deacetylase inhibition impacts sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid most cancers cells. Thyroid. 2013;23(7):838–46.
Li Q, Zhang L, Lang J, Tan Z, Feng Q, Zhu F, Liu G, Ying Z, Yu X, Feng H, Yi H, Wen Q, Jin T, Cheng Ok, Zhao X, Ge M. Lipid-peptide-mRNA nanoparticles increase radioiodine uptake in anaplastic thyroid most cancers. Adv Sci. 2023;10(3):e2204334.
Jannin A, Escande A, Al Ghuzlan A, Blanchard P, Hartl D, Chevalier B, Deschamps F, Lamartina L, Lacroix L, Dupuy C, Baudin E. Anaplastic thyroid carcinoma: an replace. Cancers. 2022;14(4):1061.
Kim HS, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park Ok, Han J, Ahn MJ. Scientific influence of phosphorylated sign transducer and activator of transcription 3, epidermal progress issue receptor, p53, and vascular endothelial progress issue receptor 1 expression in resected adenocarcinoma of lung by utilizing tissue microarray. Most cancers. 2010;116(3):676–85.
Fang S, Cheng W, Zhang M, Yang R. Affiliation of TP53 mutations with response to anlotinib therapy in superior non-small cell lung most cancers. Onco Targets Ther. 2020;13:6645–50.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A. Molecular targets of tyrosine kinase inhibitors in thyroid most cancers. Semin Most cancers Biol. 2022;79:180–96.
Liu L, Li D, Chen Z, Yang J, Ma Y, Cai H, Shan C, Lv Z, Zhang X. Wild-type P53 induces sodium/iodide symporter expression permitting radioiodide remedy in anaplastic thyroid most cancers. Cell Physiol Biochem. 2017;43(3):905–14.
Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Proof that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas as a consequence of BRAF and p53 mutations. Most cancers. 2005;103(11):2261–8.
Yoo SK, Music YS, Lee EK, Hwang J, Kim HH, Jung G, Kim YA, Kim SJ, Cho SW, Gained JK, Chung EJ, Shin JY, Lee KE, Kim JI, Park YJ, Search engine marketing JS. Integrative evaluation of genomic and transcriptomic traits related to development of aggressive thyroid most cancers. Nat Commun. 2019;10(1):2764.
Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in scientific growth. J Hematol Oncol. 2018;11(1):120.
Ruan X, Shi X, Dong Q, Yu Y, Hou X, Music X, Wei X, Chen L, Gao M. Antitumor results of anlotinib in thyroid most cancers. Endocr Relat Most cancers. 2019;26(1):153–64.
Zhou AP, Bai Y, Music Y, Luo H, Ren XB, Wang X, Shi B, Fu C, Cheng Y, Liu J, Qin S, Li J, Li H, Bai X, Ye D, Wang J, Ma J. Anlotinib versus sunitinib as first-line therapy for metastatic renal cell carcinoma: a randomized section II scientific trial. Oncologist. 2019;24(8):e702–8.
Xu Q, Huang Ok, Meng X, Weng Y, Zhang L, Bu L, Zheng X, Cai J, Zhan R, Chen Q. Security and efficacy of anlotinib hydrochloride plus temozolomide in sufferers with recurrent glioblastoma. Clin Most cancers Res. 2023;29(19):3859–66.
Elzoghby AO, Samy WM, Elgindy NA. Protein-based nanocarriers as promising drug and gene supply techniques. J Management Launch. 2012;161(1):38–49.
Guo L, Zhang H, Liu P, Mi T, Ha D, Su L, Huang L, Shi Y, Zhang J. Preclinical evaluation of paclitaxel- and trastuzumab-delivering magnetic nanoparticles Fe(3)O(4) for therapy and imaging of HER2-positive breast most cancers. Entrance Med. 2021;8: 738775.
Wang Q, Sui G, Wu X, Teng D, Zhu L, Guan S, Ran H, Wang Z, Wang H. A sequential focusing on nanoplatform for anaplastic thyroid carcinoma theranostics. Acta Biomater. 2020;102:367–83.
Huang S, Zhang L, Xu M, Li C, Fu H, Huang J, Jin X, Liang S, Wang H. Co-delivery of (131) I and prima-1 by self-assembled CD44-targeted nanoparticles for anaplastic thyroid carcinoma theranostics. Adv Healthc Mater. 2021;10(3): e2001029.
Li J, Zhang L, Liu Y, Wen J, Wu D, Xu D, Segura T, Jin J, Lu Y, Wang H. An intracellular protein supply platform primarily based on glutathione-responsive protein nanocapsules. Chem Commun. 2016;52(93):13608–11.
Wu J, Liang J, Liu R, Lv T, Fu Ok, Jiang L, Ma W, Pan Y, Tan Z, Liu Q, Qiu W, Ge M, Wang J. Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid most cancers. Endocr Relat Most cancers. 2023. https://doi.org/10.1530/ERC-23-0036.
Liang J, Jin Z, Kuang J, Feng H, Zhao Q, Yang Z, Zhan L, Shen B, Yan J, Cai W, Cheng X, Qiu W. The function of anlotinib-mediated EGFR blockade in a optimistic suggestions loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid most cancers angiogenesis. Br J Most cancers. 2021;125(3):390–401.
Wang C, Zhang R, Tan J, Meng Z, Zhang Y, Li N, Wang H, Chang J, Wang R. Impact of mesoporous silica nanoparticles co-loading with 17-AAG and Torin2 on anaplastic thyroid carcinoma by focusing on VEGFR2. Oncol Rep. 2020;43(5):1491–502.
Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, Patrizio A, Vita R, Benvenga S, Materazzi G, Fallahi P, Antonelli A. Novel remedies for anaplastic thyroid carcinoma. Gland Surg. 2020;9(Suppl 1):S28-s42.
Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, Milas ZL, Galer CE, Henderson YC, Jasser SA, Schwartz DL, Bankson JA, Myers JN, Lai SY. Focused remedy of VEGFR2 and EGFR considerably inhibits progress of anaplastic thyroid most cancers in an orthotopic murine mannequin. Clin Most cancers Res. 2011;17(8):2281–91.
Gomez-Rivera F, Santillan-Gomez AA, Younes MN, Kim S, Fooshee D, Zhao M, Jasser SA, Myers JN. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial progress issue receptor signaling and progress of anaplastic thyroid most cancers in an orthotopic nude mouse mannequin. Clin Most cancers Res. 2007;13(15 Pt 1):4519–27.
Zheng X, Wang J, Ye T, Tang W, Pan X, Wang S, Liu J. Efficacy and security of anlotinib-based chemotherapy for regionally superior or metastatic anaplastic thyroid carcinoma. Endocrine. 2023;81(3):540–6.
Ejigah V, Owoseni O, Bataille-Backer P, Ogundipe OD, Fisusi FA, Adesina SK. Approaches to enhance macromolecule and nanoparticle accumulation within the tumor microenvironment by the improved permeability and retention impact. Polymers. 2022;14(13):2601.
Shinde VR, Revi N, Murugappan S, Singh SP, Rengan AK. Enhanced permeability and retention impact: a key facilitator for strong tumor focusing on by nanoparticles. Photodiagn Photodyn Ther. 2022;39: 102915.
Yang C, Tan Y, Qi H, Zhou J, Lengthy L, Zhan Q, Wang Y, Yuan X, Kang C. Boosting of the improved permeability and retention impact with nanocapsules improves the therapeutic results of cetuximab. Most cancers Biol Med. 2020;17(2):433–43.
Zou X, Jiang Z, Li L, Huang Z. Selenium nanoparticles coated with pH responsive silk fibroin complicated for fingolimod launch and enhanced focusing on in thyroid most cancers. Synthetic Cells Nanomed Biotechnol. 2021;49(1):83–95.
Shi Y, van der Meel R, Chen X, Lammers T. The EPR impact and past: methods to enhance tumor focusing on and most cancers nanomedicine therapy efficacy. Theranostics. 2020;10(17):7921–4.
Kang H, Rho S, Stiles WR, Hu S, Baek Y, Hwang DW, Kashiwagi S, Kim MS, Choi HS. Measurement-dependent EPR impact of polymeric nanoparticles on tumor focusing on. Adv Healthcare Mater. 2020;9(1): e1901223.
Schumann S, Scherthan H, Pfestroff Ok, Schoof S, Pfestroff A, Hartrampf P, Hasenauer N, Buck AK, Luster M, Port M, Lassmann M, Eberlein U. DNA harm and restore in peripheral blood mononuclear cells after inside ex vivo irradiation of affected person blood with (131)I. Eur J Nucl Med Mol Imaging. 2022;49(5):1447–55.
Liang S, Jin X, Ma Y, Guo J, Wang H. Folic acid-conjugated BSA nanocapsule (n-BSA–FA) for most cancers focused radiotherapy and imaging. RSC Adv. 2015;5(108):88560–6.
Han Y, Wang J, Solar T, Ouyang Q, Li J, Yuan J, Xu B. Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic remedy with a VEGFR inhibitor anlotinib for pretreated superior triple unfavorable breast most cancers. Sign Transduct Goal Ther. 2023;8(1):429.
Liu Y, Du J, Yan M, Lau MY, Hu J, Han H, Yang OO, Liang S, Wei W, Wang H, Li J, Zhu X, Shi L, Chen W, Ji C, Lu Y. Biomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxication. Nat Nanotechnol. 2013;8(3):187–92.
Prasad R, Aiyer S, Chauhan DS, Srivastava R, Selvaraj Ok. Bioresponsive carbon nano-gated multifunctional mesoporous silica for most cancers theranostics. Nanoscale. 2016;8(8):4537–46.
Chauhan DS, Kumawat MK, Prasad R, Reddy PK, Dhanka M, Mishra SK, Bahadur R, Neekhra S, De A, Srivastava R. Plasmonic carbon nanohybrids for repetitive and extremely localized photothermal most cancers remedy, colloids and surfaces. B, Biointerfaces. 2018;172:430–9.
Prasad R, Jain NK, Yadav AS, Jadhav M, Radharani NNV, Gorain M, Kundu GC, Conde J, Srivastava R. Ultrahigh penetration and retention of graphene quantum dot mesoporous silica nanohybrids for picture guided tumor regression. ACS Appl Bio Mater. 2021;4(2):1693–703.
Bindra AK, Sreejith S, Prasad R, Gorain M, Thomas R, Jana D, Nai MH, Wang D, Tharayil A, Kundu GC, Srivastava R, Thomas S, Lim CT, Zhao Y. A plasmonic supramolecular nanohybrid as a distinction agent for site-selective computed tomography imaging of tumor. Adv Funct Mater. 2022;32(12):2110575.
Li R, Yan J, Xie L, Zhang Y, Gao J, Liu Q, Lin Z, Jiang P, Qian H, Yang M, Wu F, Jiang X, Liu B, Wang L. Facile optimization and analysis of PEG-PCL block copolymeric nanoparticles for anticancer drug supply utilizing copolymer hybrids and histoculture drug response assays. J Biomed Nanotechnol. 2018;14(2):321–30.
Solar CY, Shen S, Xu CF, Li HJ, Liu Y, Cao ZT, Yang XZ, Xia JX, Wang J. Tumor acidity-sensitive polymeric vector for energetic focused siRNA supply. J Am Chem Soc. 2015;137(48):15217–24.
Zhang L, Liu Y, Liu G, Xu D, Liang S, Zhu X, Lu Y, Wang H. Prolonging the plasma circulation of proteins by nano-encapsulation with phosphorylcholine-based polymer. Nano Res. 2016;9(8):2424–32.
Liang S, Liu Y, Jin X, Liu G, Wen J, Zhang L, Li J, Yuan X, Chen ISY, Chen W, Wang H, Shi L, Zhu X, Lu Y. Phosphorylcholine polymer nanocapsules delay the circulation time and scale back the immunogenicity of therapeutic proteins. Nano Res. 2016;9(4):1022–31.
Janković J, Tatić S, Božić V, Živaljević V, Cvejić D, Paskaš S. Inverse expression of caveolin-1 and EGFR in thyroid most cancers sufferers. Hum Pathol. 2017;61:164–72.
Milosevic Z, Pesic M, Stankovic T, Dinic J, Milovanovic Z, Stojsic J, Dzodic R, Tanic N, Bankovic J. Concentrating on RAS-MAPK-ERK and PI3K-AKT-mTOR sign transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl Res. 2014;164(5):411–23.
Lorusso L, Pieruzzi L, Biagini A, Sabini E, Valerio L, Giani C, Passannanti P, Pontillo-Contillo B, Battaglia V, Mazzeo S, Molinaro E, Elisei R. Lenvatinib and different tyrosine kinase inhibitors for the therapy of radioiodine refractory, superior, and progressive thyroid most cancers. Onco Targets Ther. 2016;9:6467–77.
Lee DH, Lee GK, Kong SY, Kook MC, Yang SK, Park SY, Park SH, Keam B, Park DJ, Cho BY, Kim SW, Chung KW, Lee ES, Kim SW. Epidermal progress issue receptor standing in anaplastic thyroid carcinoma. J Clin Pathol. 2007;60(8):881–4.
